Overview

Dose Ranging, Switch Study of Islatravir (ISL) and MK-8507 Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

Status:
Active, not recruiting

Trial end date:
2024-06-06

Target enrollment:

Participant gender:

Summary

This is a randomized, controlled, double-blind, dose-ranging study evaluating a switch to islatravir (ISL) and MK-8507 once-weekly in adult participants with human immunodeficiency virus type 1 (HIV-1) who have been virologically suppressed for ≥6 months on bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) once-daily. The primary objectives are to evaluate the antiretroviral activity, safety, and tolerability of ISL with different doses of MK-8507 compared to continued BIC/FTC/TAF treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

4'-ethynyl-2-fluoro-2'-deoxyadenosine
Islatravir